- Report
- October 2023
- 80 Pages
Germany
From €2492EUR$2,595USD£2,146GBP
- Report
- October 2023
- 80 Pages
France
From €2492EUR$2,595USD£2,146GBP
- Report
- February 2022
- 154 Pages
Global
From €3458EUR$3,600USD£2,977GBP
- Report
- February 2022
- 54 Pages
North America
From €1441EUR$1,500USD£1,240GBP
- Clinical Trials
- December 2019
- 290 Pages
Global
From €2401EUR$2,500USD£2,067GBP
- Report
- June 2019
- 114 Pages
Global
From €10560EUR$10,995USD£9,092GBP
- Report
- March 2024
- 58 Pages
Mexico
From €2161EUR$2,250USD£1,861GBP
- Report
- March 2024
- 60 Pages
From €2833EUR$2,950USD£2,439GBP
- Book
- June 2022
- 800 Pages
From €158EUR$165USD£136GBP
- Report
- February 2022
- 80 Pages
Africa
From €3645EUR$3,795USD£3,138GBP
- Report
- February 2022
- 40 Pages
Brazil
From €2492EUR$2,595USD£2,146GBP
- Report
- February 2022
- 40 Pages
China
From €2492EUR$2,595USD£2,146GBP
- Report
- February 2022
- 40 Pages
France
From €2492EUR$2,595USD£2,146GBP
- Report
- February 2022
- 40 Pages
Germany
From €2492EUR$2,595USD£2,146GBP
- Report
- February 2022
- 40 Pages
Ireland
From €2492EUR$2,595USD£2,146GBP
- Report
- February 2022
- 40 Pages
Japan
From €2492EUR$2,595USD£2,146GBP
- Report
- February 2022
- 40 Pages
Russia
From €2492EUR$2,595USD£2,146GBP
- Report
- February 2022
- 40 Pages
South Korea
From €2492EUR$2,595USD£2,146GBP
- Report
- February 2022
- 40 Pages
United States
From €2492EUR$2,595USD£2,146GBP
- Report
- February 2022
- 40 Pages
Vietnam
From €2492EUR$2,595USD£2,146GBP
Schizophrenia is a mental disorder characterized by abnormal social behavior and a distorted perception of reality. It is one of the most disabling and emotionally devastating mental illnesses, affecting approximately 1% of the population worldwide. Symptoms of schizophrenia can include hallucinations, delusions, disorganized speech and behavior, and cognitive deficits.
The schizophrenia market within the context of mental health is a rapidly growing sector, driven by the increasing prevalence of the disorder and the need for better treatments. The market is expected to benefit from the development of novel drugs and therapies, as well as the increasing awareness of mental health issues. Additionally, the increasing focus on personalized medicine and the development of digital health technologies are expected to drive the market growth.
Some of the key players in the schizophrenia market include Eli Lilly, Johnson & Johnson, Novartis, Pfizer, Otsuka Pharmaceutical, Sunovion Pharmaceuticals, Allergan, and Merck. Show Less Read more